BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 24696421)

  • 1. Detection of breast cancer from blood through analysis of lymphocyte fluorescent intensity using MUC1 antigen.
    Armon-Omer A; Hadary A; Hilu G; Tayar BE; Keren T; Sharabi-Nov A; Bickel A; Klein O
    Breast Cancer; 2015 Nov; 22(6):626-33. PubMed ID: 24696421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of circulating tumor cells in breast cancer patients utilizing multiparameter flow cytometry and assessment of the prognosis of patients in different CTCs levels.
    Hu Y; Fan L; Zheng J; Cui R; Liu W; He Y; Li X; Huang S
    Cytometry A; 2010 Mar; 77(3):213-9. PubMed ID: 20169594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An approach for high sensitivity detection of breast cancer by analysis of changes in structure of the cytoplasmic matrix of lymphocytes specifically induced by a specific breast tumour antigen (MUC-l/SEC).
    Klein O; Linn S; Hadari A; Davidson C; Eitan A; Zidan J; Kook AI
    Breast; 2002 Apr; 11(2):137-43. PubMed ID: 14965660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of mucin 1 possessing a 3'-sulfated core1 in recurrent and metastatic breast cancer.
    Ideo H; Hinoda Y; Sakai K; Hoshi I; Yamamoto S; Oka M; Maeda K; Maeda N; Hazama S; Amano J; Yamashita K
    Int J Cancer; 2015 Oct; 137(7):1652-60. PubMed ID: 25787775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a panel of complex autoantigens (LGALS3, PHB2, MUC1, and GK2) in combination with CA15-3 for the diagnosis of early-stage breast cancer.
    Zuo X; Chen L; Liu L; Zhang Z; Zhang X; Yu Q; Feng L; Zhao X; Qin T
    Tumour Biol; 2016 Jan; 37(1):1309-17. PubMed ID: 26289852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-MUC1 Antibody in Nipple Aspirate Fluids Correlates with Tumor Aggressiveness in Breast Cancer: A Feasibility Study.
    Menekse E; McKolanis J; Finn OJ; McAuliffe PF; Johnson R; Soran A
    Dis Markers; 2015; 2015():179689. PubMed ID: 26693201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue and serum MUC1 mucin detection in breast cancer patients.
    Croce MV; Isla-Larrain MT; Demichelis SO; Gori JR; Price MR; Segal-Eiras A
    Breast Cancer Res Treat; 2003 Oct; 81(3):195-207. PubMed ID: 14620915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flow cytometry-based assay to evaluate human serum MUC1-Tn antibodies.
    Van Elssen CH; Clausen H; Germeraad WT; Bennet EP; Menheere PP; Bos GM; Vanderlocht J
    J Immunol Methods; 2011 Feb; 365(1-2):87-94. PubMed ID: 21194532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autoantibodies against TYMS and PDLIM1 proteins detected as circulatory signatures in Indian breast cancer patients.
    Gupta P; Suman S; Mishra M; Mishra S; Srivastava N; Kumar V; Singh PK; Shukla Y
    Proteomics Clin Appl; 2016 May; 10(5):564-73. PubMed ID: 27068564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of MUC1 mucin as an escape mechanism of breast cancer cells from autologous cytotoxic T-lymphocytes.
    Kontani K; Taguchi O; Narita T; Izawa M; Hiraiwa N; Zenita K; Takeuchi T; Murai H; Miura S; Kannagi R
    Br J Cancer; 2001 May; 84(9):1258-64. PubMed ID: 11336479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a new panel of serum autoantibodies associated with the presence of in situ carcinoma of the breast in younger women.
    Desmetz C; Bascoul-Mollevi C; Rochaix P; Lamy PJ; Kramar A; Rouanet P; Maudelonde T; Mangé A; Solassol J
    Clin Cancer Res; 2009 Jul; 15(14):4733-41. PubMed ID: 19584157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization and enumeration of cells secreting tumor markers in the peripheral blood of breast cancer patients.
    Alix-Panabières C; Brouillet JP; Fabbro M; Yssel H; Rousset T; Maudelonde T; Choquet-Kastylevsky G; Vendrell JP
    J Immunol Methods; 2005 Apr; 299(1-2):177-88. PubMed ID: 15914200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mucin gene (MUC1) transfer into human dendritic cells by cationic liposomes and recombinant adenovirus.
    Pecher G; Spahn G; Schirrmann T; Kulbe H; Ziegner M; Schenk JA; Sandig V
    Anticancer Res; 2001; 21(4A):2591-6. PubMed ID: 11724326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA methylation array analyses identified breast cancer-associated HYAL2 methylation in peripheral blood.
    Yang R; Pfütze K; Zucknick M; Sutter C; Wappenschmidt B; Marme F; Qu B; Cuk K; Engel C; Schott S; Schneeweiss A; Brenner H; Claus R; Plass C; Bugert P; Hoth M; Sohn C; Schmutzler R; Bartram CR; Burwinkel B
    Int J Cancer; 2015 Apr; 136(8):1845-55. PubMed ID: 25213452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum DPPIV activity and CD26 expression on lymphocytes in patients with benign or malignant breast tumors.
    Erić-Nikolić A; Matić IZ; Dorđević M; Milovanović Z; Marković I; Džodić R; Inić M; Srdić-Rajić T; Jevrić M; Gavrilović D; Cordero OJ; Juranić ZD
    Immunobiology; 2011 Aug; 216(8):942-6. PubMed ID: 21281985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunological assessment of cryotherapy in breast cancer patients.
    Koido S; Kinoshita S; Mogami T; Kan S; Takakura K; Okamoto M; Homma S; Ohkusa T; Tajiri H; Harada J
    Anticancer Res; 2014 Sep; 34(9):4869-76. PubMed ID: 25202068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integration of Serum Protein Biomarker and Tumor Associated Autoantibody Expression Data Increases the Ability of a Blood-Based Proteomic Assay to Identify Breast Cancer.
    Henderson MC; Hollingsworth AB; Gordon K; Silver M; Mulpuri R; Letsios E; Reese DE
    PLoS One; 2016; 11(8):e0157692. PubMed ID: 27508384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic importance of S100A9 and S100A12 in breast cancer.
    Gunaldi M; Okuturlar Y; Gedikbasi A; Akarsu C; Karabulut M; Kural A
    Biomed Pharmacother; 2015 Dec; 76():52-6. PubMed ID: 26653550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumour-Associated Autoantibodies as Diagnostic Biomarkers for Breast Cancer: A Systematic Review and Meta-Analysis.
    Xia J; Shi J; Wang P; Song C; Wang K; Zhang J; Ye H
    Scand J Immunol; 2016 Jun; 83(6):393-408. PubMed ID: 26991924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased serum miR-181a is a potential new tool for breast cancer screening.
    Guo LJ; Zhang QY
    Int J Mol Med; 2012 Sep; 30(3):680-6. PubMed ID: 22692639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.